|
Mark A. Demitrack, MD, Chief Medical Officer
Dr. Demitrack is a psychiatrist with 20 years of experience in the treatment
and study of mood disorders and related conditions. He was previously Assistant
Vice President of Neuroscience at Wyeth, where he directed post marketing clinical
development in support of the Effexor XR brand. Prior to Wyeth, Dr. Demitrack was
Medical Director for the New Antidepressant Team at Lilly Research Laboratories.
During his tenure at Lilly, he oversaw the registration development and NDA
submission of the novel antidepressant, Duloxetine. Prior to his industry
experience, he served on the faculty of the University of Michigan Medical Center
Department of Psychiatry where he pursued research activities in the neuroendocrine
correlates of chronic fatigue syndrome and fibromyalgia, and served as Director of
the Michigan Eating Disorders Program. Dr. Demitrack has published extensively on
the neuroendocrinology of mood disorders.
Back
|
|
Find a NeuroStar TMS Therapy Provider Near You
If you or a loved one is suffering from major depression, you can find a NeuroStar TMS Therapy provider in your area.
Provide NeuroStar TMS Therapy in Your Practice
Provide your patients the new way back with NeuroStar TMS Therapy®. Contact us to find out how you can begin providing therapy.
|